Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apomorphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | PKM | P14618 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apomorphine SCHEMBL29414090 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL29358024 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| (S)Apomorphine SCHEMBL30554804 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL29599870 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL5605456 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| (S)Apomorphine SCHEMBL6922802 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL1923763 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL8524 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL5904190 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| (S)Apomorphine SCHEMBL19469972 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 28835 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075410-A | Dry powder composition for intranasal delivery | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026106939-A1 | IMPROVING SYMPTOMS IN MID- TO LATE-STAGE PARKINSON'S DISEASE PATIENTS USING WITH DEEP BRAIN STIMULATION | VANDERBILT UNIVERSITY (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4743090-A1 | LIPOSOME ENCAPSULATED APOMORPHINE | Liposome Holdings Limited (NZ) | 2026-05-20 | — | — | EP | claimed |
| CN-121753757-B | Construction method and application of parkinsonism animal model for improving survival rate | 杭州市第一人民医院(西湖大学附属杭州市第一人民医院) | 2026-05-15 | — | — | CN | claimed |
| US-20260131140-A1 | MODIFYING EARLY-STAGE PARKINSON'S DISEASE PROGRESSION WITH DEEP BRAIN STIMULATION | VANDERBILT UNIV (US) | 2026-05-14 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| WO-2026088039-A1 | ENCAPSULATED APOMORPHINE COMPOSITIONS | MASSEY VENTURES LIMITED (NZ) | 2026-04-30 | — | — | WO | claimed |
| EP-0178029-A2 | Detergent compositions containing compatible organic emetic agent | THE PROCTER & GAMBLE COMPANY (US) | 1986-04-16 | — | — | EP | claimed |
| US-4473640-A | OF DRUG-GLUCURONIC ACID COMPLEXES | COMBIE JOAN D | 1984-09-25 | — | — | US | claimed |
| US-4430435-A | MIXING DOPAMINE RECEPTOR MATERIAL, RADIOALTIVE LABELED BINDER, PHOSPHATE BLOCKING AGENT AND MEASUREMENT OF RADIOACTIVITY | BURROUGHS WELLCOME CO. (US) | 1984-02-07 | — | — | US | claimed |
| EP-0091511-A2 | 1-(3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl)-4-(substituted)-piperazines and -piperidines, a process for the preparation thereof, pharmaceutical compositions containing the same and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1983-10-19 | — | — | EP | claimed |
| EP-0077393-A1 | NOVEL METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME | The University of Kentucky Research Foundation (US) | 1983-04-27 | — | — | EP | claimed |
| WO-1982003768-A1 | NOVEL METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME | UNIV KENTUCKY (US) | 1982-11-11 | — | — | WO | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
| US-4202897-A | IMIDAZON2,1-AE ISOINDOLES AND ISOQUINOLINES | SANDOZ, INC. (US) | 1980-05-13 | — | — | US | claimed |
| US-4197288-A | Neuroleptic radioreceptor assay method and kit | BURROUGHS WELLCOME CO. (US) | 1980-04-08 | — | — | US | claimed |
| US-4162361-A | ORTHOPHOSPHORIC | STERLING DRUG INC. (US) | 1979-07-24 | — | — | US | claimed |